期刊
JOURNAL OF PERSONALIZED MEDICINE
卷 12, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/jpm12020246
关键词
depression; glutamate; H4; hippocampus; JNJ7777120
资金
- Ataturk University Scientific Research Projects [TSA-2019-6994]
- Erzurum, Turkey
Glutamate release and reuptake play a key role in depression, and the drug JNJ7777120 increases the activity of glutamate transporters, improving neuron viability and behavioral ability, thereby preventing and treating depression effectively.
Glutamate release and reuptake play a key role in the pathophysiology of depression. glutamatergic nerves in the hippocampus region are modulated by histaminergic afferents. Excessive accumulation of glutamate in the synaptic area causes degeneration of neuron cells. The H4 receptor is defined as the main immune system histamine receptor with a pro-inflammatory role. To understand the role of this receptor, the drug JNJ7777120 was used to reveal the chronic depression-glutamate relationship. We have important findings showing that the H4 antagonist increases the glutamate transporters' instantaneous activity. In our experiment, it has been shown that blocking the H4 receptor leads to increased neuron cell viability and improvement in behavioral ability due to glutamate. Therefore, JNJ can be used to prevent neurotoxicity, inhibit membrane phospholipase activation and free radical formation, and minimize membrane disruption. In line with our findings, results have been obtained that indicate that JNJ will contribute to the effective prevention and treatment of depression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据